Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Toshiomi Nakate"'
Autor:
Takahiro Wakayama, Toshiomi Nakate, Tomoko Watanabe, Momoko Inada, Satoshi Kitamura, Munekazu Kanda, Kazumi Yamamori
Publikováno v:
BUNSEKI KAGAKU. 62:333-338
Autor:
Atsuo Ohike, Hiromitsu Yoshida, Rinta Ibuki, Yuji Tokunaga, Yoshiaki Kawashima, Toshiomi Nakate
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 56:319-325
FK224 is a cyclopeptide drug with poor oral absorption due to proteolysis in the gastrointestinal tract. The objectives of this study were to investigate the absorption of FK224 from the lung in healthy volunteers, and compare the pharmacokinetic pro
Autor:
Yoshiaki Kawashima, Hiromitsu Yoshida, Toshiomi Nakate, Yuji Tokunaga, Rinta Ibuki, Atsuo Ohike
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 59(1)
FK888 is a candidate selective NK1 receptor antagonist, and it exhibits poor absorption from the gastrointestinal tract in healthy volunteers. In a previous study, the optimized dry powder inhaler (DPI) formulation with carrier lactose using the Spin
Autor:
Toshiomi Nakate, Kazutaka Higaki, Kazuto Okimoto, Kazunari Yamashita, Rinta Ibuki, Toshikiro Kimura, Yuji Tokunaga, Atsuo Ohike
Publikováno v:
International journal of pharmaceutics. 267(1-2)
The aim of this study was to establish a new preparation method for solid dispersion formulation (SDF) of tacrolimus, a poorly water-soluble drug, without dichloromethane, because no use of dichloromethane is recommended by ICH harmonized tripartite
Autor:
Atsuo Ohike, Yuji Tokunaga, Toshiomi Nakate, Rinta Ibuki, Hiromitsu Yoshida, Yoshiaki Kawashima
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 97(1)
(4 R )-4-Hydroxy-l-[(l-methyl-l H -indol-3-yl)carbonyl]- l -prolyl- N -benzyl- N -methyl-3-(2-naphthyl)- l -alaninamide (FK888) is a candidate selective NK1 receptor antagonist, and it exhibits poor absorption from the gastrointestinal (GI) tract in
Autor:
Yuji Tokunaga, Atsuo Ohike, Toshiomi Nakate, Yoshiaki Kawashima, Rinta Ibuki, Hiromitsu Yoshida
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 55(2)
FK224 is a cyclopeptide drug with a low aqueous solubility. Following oral administration to rats, poor absorption was observed due to proteolysis in the gastrointestinal tract. The objective of this study was to investigate the effect of the pulmona